Fig. 5
From: Functionalized nanoparticles with targeted antibody to enhance imaging of breast cancer in vivo
MRI signal enhancement in tumors from mice injected with G5-Gd-Trastuzumab or G5-Gd. Quantitation of signal enhancement in mice receiving G5-Gd-Trastuzumab (circles) vs. G5-Gd (Xs) at 1, 4, 24 and 48 h post injection (left panel). Difference between the two treatments is statistically significant (P < 0.001) at all the measured time points. Results are shown as mean ± standard deviation of the pixel intensities in the tumor. Biodistribution time course shows persistence of signal in the tumor as compared to urinary excretion (bladder imaging, right panel). SEM was used for error bars, n = 10